Proven Track Record of Most Accurate Analysis
Proven Track Record
of Most Accurate Analysis
Our proprietary algorithms continue to show that smart money is selling Research In Motion (RIMM) on all up moves. Please earlier posts for more details.
An analysis of 30 years of data in 15 emerging markets reveals that big money in the emerging markets is consistently made by paying attention to geopolitical events. The key to profits lies in recognizing change before the crowd using a proven method such as the ZYX Change Method. The diagram below depicts the basics of the this method. click to enlarge Take a look at the long term chart of Morgan Stanley India Fund (IIF) and, see how it followed the five stages predicted by our method when the 2008 financial crash is excluded. Those who recognized the political
The following post on St Joe Company (JOE ) appeared this morning in the Real Time Feed of the ZYX Buy Change Alert. Joe has entered into an agreement with Fairholme, its largest shareholder, permitting it to acquire beneficial ownership of up to 50% of outstanding common stock. Joe, the largest landowner in Florida, had previously approved Fairholme’s acquisition of beneficial ownership of up to 30% of outstanding common stock. Those in the stock should continue to hold. Those not in the stock may enter on a pullback.
Research in Motion (RIMM) has moved up from its morning lows. Our Smart MoneyIndicator shows that smart money is selling Research In Motion into the strength.
Readers may want to start from my previous article on Research In Motion titled What Is The True Value Of Research In Motion? In the article I described various scenarios for Research In Motion (RIMM). One of the scenarios I described was for Research in Motion to continue on its present path. The earnings report just issued shows that prediction is coming true. The earnings for the quarter were $0.80 compared to the consensus of $0.88. Revenues for the quarter fell 10% to $4.17 billion compared to the consensus of $4.47 billion. For the next quarter, the company projects revenues
It is time to take profits on Acorda Therapeutics (ACOR). Consider taking profits on the entire position of Acorda Therapeutics right here at $23.08. Ampyra, the drug that has caused most excitement in Acora Therapeutics, is not proving to be a very good drug as we had predicted. Please see prior post on Acorda Therapeutics. However, this is company is highly promotional and periodically tends to release meaningless press releases that run the stock up. The plan is to short Acorda Therapeutics again on any run up. A signal will be provided in real-time on the
Vivus (VVUS ) shares have moved up strongly on the news that FDA has agreed to an early re-submission of the QNEXA NDA for the treatment of obesity. The road is not all clear for Vivus. There are still major issues that need to be resolved by Vivus including birth defect concerns, cardiovascular concerns, and epilepsy concerns. If and when six screens of the ZYX Change Method are satisfied, we will issue a buy signal on the Real Time Feed of the ZYX Buy Change Alert.
We are taking partial profits on a 5% tranche of Pan American Silver (PAAS) at $31.82.